Tonix Pharmaceuticals (Tonix Pharmaceuticals Holding Corp.) is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| TNXP | Tonix Pharmaceuticals Holding Corp. | 2025-10-16 20:03:25 | 19.33 | 0.52 | 2.76 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TNXP | 0001430306 | Tonix Pharmaceuticals Holding Corp. | US8902608392 | 529900ACPKP9QW20GX48 | 261434750 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | NV | 26 MAIN STREET, SUITE 101 | CHATHAM | NJ | 07928 | UNITED STATES | US | 212-980-9155 | 26 MAIN STREET, SUITE 101, CHATHAM, NJ, 07928 | 26 MAIN STREET, SUITE 101, CHATHAM, NJ, 07928 | TAMANDARE EXPLORATIONS INC. | Biotechnology | — | — | — | http://www.tonixpharma.com | 6,857,126 | 7,546,276 | 8,765,896 | Tonix Pharmaceuticals (Tonix Pharmaceuticals Holding Corp.) is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project. | 2025-10-10 22:20:53 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 6,857,126 | -10,139,157 | -59.6551 | 6,434,881 | -78,055,981 | -92.3839 |
| 2023 | 16,996,283 | -33,025,871 | -66.0225 | 84,490,862 | 21,951,365 | 35.1 |
| 2022 | 50,022,154 | -334,099,786 | -86.9775 | 62,539,497 | -471,389,127 | -88.2869 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Gregory Sullivan | Chief Medical Officer | 2024 | 499,200 | 182,208 | 0 | 0 | 0 | 922,444 |
| Bradley Saenger | Chief Financial Officer | 2024 | 483,600 | 176,514 | 0 | 0 | 0 | 849,981 |
| Jessica Morris | Chief Operations Officer | 2024 | 494,000 | 180,310 | 0 | 0 | 0 | 887,741 |
| Gregory Sullivan | Chief Medical Officer | 2023 | 480,000 | 181,440 | 0 | 0 | 0 | 951,998 |
| Jessica Morris | Chief Operations Officer | 2023 | 475,000 | 179,550 | 0 | 0 | 0 | 928,599 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 81 |
| 2023 | 103 |
| 2022 | 117 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 10,094,000 | 7,768,000 | — |
| Cost Of Revenue | 7,765,000 | 4,741,000 | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 39,972,000 | 86,655,000 | 81,876,000 |
| General And Administrative Expenses | 40,101,000 | 34,752,000 | 30,215,000 |
| Operating Expenses | 146,795,000 | 126,148,000 | 112,091,000 |
| Operating Income | -136,701,000 | -118,380,000 | -112,091,000 |
| Net Income | -130,036,000 | -116,658,000 | -110,218,000 |
| Earnings Per Share Basic | -176.6 | -6.85 | -3.27 |
| Earnings Per Share Diluted | -176.6 | -6.85 | -3.27 |
| Weighted Average Shares Outstanding Basic | 736,339 | 17,039,309 | 35,739,057 |
| Weighted Average Shares Outstanding Diluted | 736,339 | 17,039,309 | 35,739,057 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 98,776,000 | 24,948,000 | 120,229,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 3,683,000 | 4,590,000 | — |
| Inventories | 8,408,000 | 13,639,000 | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 119,002,000 | 47,768,000 | 130,777,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 42,252,000 | 94,028,000 | 93,814,000 |
| Other Assets Non Current | 951,000 | 1,129,000 | 384,000 |
| Total Assets Non Current | 43,888,000 | 106,689,000 | 94,913,000 |
| Total Assets | 162,890,000 | 154,457,000 | 225,690,000 |
| Accounts Payable | 4,546,000 | 3,782,000 | 8,068,000 |
| Deferred Revenue | 1,816,000 | 2,980,000 | — |
| Short Term Debt | 2,820,000 | 2,350,000 | — |
| Other Liabilities Current | — | 44,000 | — |
| Total Liabilities Current | 18,307,000 | 18,884,000 | 18,180,000 |
| Long Term Debt | 8,650,000 | 11,000,000 | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 5,025,000 | 30,048,000 | 328,000 |
| Total Liabilities | 23,332,000 | 48,932,000 | 18,508,000 |
| Common Stock | 4,000 | 59,000 | 76,000 |
| Retained Earnings | -730,694,000 | -600,658,000 | -470,038,000 |
| Accumulated Other Comprehensive Income | -255,000 | -232,000 | -167,000 |
| Total Shareholders Equity | 139,558,000 | 105,525,000 | 207,182,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 2,900,000 | 3,800,000 | 1,253,000 |
| Share Based Compensation Expense | 4,778,000 | 9,275,000 | 10,914,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 3,683,000 | — | — |
| Change In Inventories | -3,741,000 | -61,000 | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 927,000 | -3,490,000 | -1,045,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -60,925,000 | -102,003,000 | -98,053,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 120,000 | 7,895,000 | 48,147,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -120,000 | -29,070,000 | -48,147,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 140,195,000 | 18,939,000 | 94,463,000 |
| Repurchase Of Common Stock | — | 13,965,000 | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | 2,350,000 | — | — |
| Other Financing Activities | 27,000 | 29,000 | 40,000 |
| Cash From Financing Activities | 134,872,000 | 36,517,000 | 87,844,000 |
| Change In Cash | 73,831,000 | -94,621,000 | -58,430,000 |
| Cash At End Of Period | 98,776,000 | 24,948,000 | 120,229,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 1,234,000 | — | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -176.6 | -6.85 | -3.27 |
| Price To Earnings Ratio | -0.1867 | -188.2628 | -2,384.0979 |
| Earnings Growth Rate | 2,478.1022 | 109.4801 | — |
| Price Earnings To Growth Ratio | -0.0001 | -1.7196 | — |
| Book Value Per Share | 189.5296 | 6.193 | 5.7971 |
| Price To Book Ratio | 0.174 | 208.234 | 1,344.8161 |
| Ebitda | -127,136,000 | -112,858,000 | -108,965,000 |
| Enterprise Value | -63,021,539.78 | 21,962,294,886.4 | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.0822 | 0.1265 | — |
| Capital Expenditures | -48,876,000 | 4,014,000 | 44,509,000 |
| Free Cash Flow | -12,049,000 | -106,017,000 | -142,562,000 |
| Return On Equity | -0.9318 | -1.1055 | -0.532 |
| One Year Beta | 1.3337 | 1.3563 | 1.2698 |
| Three Year Beta | 1.2888 | 1.3391 | 0.4679 |
| Five Year Beta | 0.5888 | 0.5979 | 0.5703 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Taylor Carolyn E. | Director | 2025-08-21 | 418 | A | 418 |
| Treco James | Director | 2025-08-20 | 250 | A | 250 |
| Hunter James Randolph Jr | Director | 2025-06-12 | 7,740 | A | 7,740 |
| LEDERMAN SETH | Director, Chief Executive Officer | 2025-05-15 | 4,000 | A | 4,005 |
| GRANGE DAVID L | Director | 2025-05-13 | 10,000 | A | 10,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| CWM, LLC | 2025-09-30 | 1,000 | 26 | 38.4615 |
| NEW YORK STATE COMMON RETIREMENT FUND | 2025-06-30 | 104,342 | 2,900 | 35.98 |
| OSAIC HOLDINGS, INC. | 2025-06-30 | 18,237 | 507 | 35.9704 |
| Equitable Holdings, Inc. | 2025-06-30 | 378,690 | 10,525 | 35.98 |
| MORGAN STANLEY | 2025-06-30 | 681,028 | 18,928 | 35.9799 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Global X Funds | 2025-07-31 | Global X Russell 2000 ETF | RSSL | 3,804 | 143,334.72 | 0.0109 |
| ProFunds | 2025-07-31 | SMALL-CAP PROFUND SERVICE CLASS | SLPSX | 7 | 263.76 | 0.0076 |
| ProFunds | 2025-07-31 | SMALL-CAP PROFUND INVESTOR CLASS | SLPIX | 7 | 263.76 | 0.0076 |
| ProFunds | 2025-07-31 | ULTRASMALL-CAP PROFUND SERVICE CLASS | UAPSX | 84 | 3,165.12 | 0.008 |
| ProFunds | 2025-07-31 | ULTRASMALL-CAP PROFUND INVESTOR CLASS | UAPIX | 84 | 3,165.12 | 0.008 |